drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Also known as SYS6010, an EGFR-targeting antibody–drug conjugate (ADC). A monoclonal antibody binds EGFR on tumor cells, is internalized, and releases a linked cytotoxic payload to kill the cancer cell. Administered intravenously every 3 weeks in Phase 1 dose escalation/expansion for EGFR-expressing solid tumors (e.g., EGFR-mutant NSCLC, head and neck, KRAS–wild-type colorectal, and breast cancers).
nci_thesaurus_concept_id
C200642
nci_thesaurus_preferred_term
Anti-EGFR Antibody-drug Conjugate CPO301
nci_thesaurus_definition
An antibody-drug conjugate (ADC) consisting of a monoclonal antibody directed against the epidermal growth factor receptor (EGFR; HER1; ErbB1) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration of anti-EGFR ADC CPO301, the monoclonal antibody moiety binds to EGFR on tumor cell surfaces. Upon binding and internalization, the cytotoxic agent is released and kills the EGFR-expressing cancer cells, through an as of yet unknown mechanism of action. EGFR, overexpressed by a variety of cancers, plays a key role in tumor cell proliferation and survival.
drug_mesh_term
Antibody-Drug Conjugates
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
An EGFR-targeted monoclonal antibody delivers an attached cytotoxic payload to EGFR-expressing tumor cells. After binding EGFR on the cell surface, the ADC is internalized and the payload is released intracellularly, inducing cancer cell death (specific payload/mechanism not disclosed).
drug_name
CPO301
nct_id_drug_ref
NCT05948865